Use of an angular transformation for ratio estimation in cost-effectiveness analysis

被引:0
|
作者
Cook, JR [1 ]
Heyse, JF [1 ]
机构
[1] Merck Res Labs, W Point, PA 19486 USA
关键词
D O I
10.1002/1097-0258(20001115)19:21<2989::AID-SIM599>3.0.CO;2-G
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Economic evaluations of medical technologies involve a consideration of both costs and clinical benefits, and an increasing number of clinical studies include a specific objective of assessing cost-effectiveness. These studies measure the trade-off between costs and benefits using the cost-effectiveness ratio (CE ratio), which is defined as the net incremental cost per unit of benefit provided by the candidate therapy. In this gaper we review the statistical methods which have been proposed for estimating 95 per cent confidence intervals for cost-effectiveness ratios. We show that the use of an angular transformation of the standardized ratio stabilizes the variance of the estimated CE ratio, and provides a clearer interpretation of study results. An estimate of the 95 per cent confidence interval for the CE ratio in the transformed scale is easily made using the jack-knife or bootstrap. The available methods are compared using data from a long term study of mortality in patients with congestive heart failure. Copyright (C) 2000 John Wiley & Sons, Ltd.
引用
收藏
页码:2989 / 3003
页数:15
相关论文
共 50 条
  • [41] The use of meta-analysis in cost-effectiveness analysis - Issues and recommendations
    Saint, S
    Veenstra, DL
    Sullivan, SD
    PHARMACOECONOMICS, 1999, 15 (01) : 1 - 8
  • [42] AN ANALYSIS OF HOW NOT TO USE COST-EFFECTIVENESS ANALYSIS FOR PRICE-SETTING
    Standaert, B.
    Ethgen, O.
    Emerson, R. A.
    Postma, M. J.
    VALUE IN HEALTH, 2013, 16 (07) : A616 - A616
  • [43] The Use of Meta-Analysis in Cost-Effectiveness AnalysisIssues and Recommendations
    Sanjay Saint
    David L. Veenstra
    Sean D. Sullivan
    PharmacoEconomics, 1999, 15 : 1 - 8
  • [44] USE OF COST-EFFECTIVENESS ANALYSIS IN PLANNING CANCER CHEMOPROPHYLAXIS TRIALS
    GUESS, HA
    RUDNICK, SA
    CONTROLLED CLINICAL TRIALS, 1983, 4 (02): : 89 - 100
  • [45] Why don't Americans use cost-effectiveness analysis?
    Neumann, PJ
    AMERICAN JOURNAL OF MANAGED CARE, 2004, 10 (05): : 308 - 312
  • [46] The use of cost-effectiveness analysis in plastic surgery clinical research
    Thoma, Achilleas
    Strumas, Nick
    Rockwell, Gloria
    McKnight, Leslie
    CLINICS IN PLASTIC SURGERY, 2008, 35 (02) : 285 - +
  • [47] USE OF MODEL AVERAGING TECHNIQUES IN COST-EFFECTIVENESS ANALYSIS IN ONCOLOGY
    Le, H. H.
    Ozer-Stillman, I
    VALUE IN HEALTH, 2014, 17 (07) : A556 - A556
  • [48] The Use of Cost-Effectiveness Analysis for Pediatric Immunization in Developing Countries
    Gauvreau, Cindy Low
    Ungar, Wendy J.
    Koehler, Jillian Clare
    Zlotkin, Stanley
    MILBANK QUARTERLY, 2012, 90 (04): : 762 - 790
  • [49] Cost-effectiveness analysis of tirofiban use in acute coronary syndromes
    Watkins, SP
    De Lemos, JA
    Tokol, G
    Mahoney, EM
    Alexopoulos, C
    Goldsman, D
    Goldsman, P
    Yegin, A
    Bunt, T
    Deuson, R
    Cannon, CP
    Hamm, CW
    Weintraub, WS
    CIRCULATION, 2001, 104 (17) : 798 - 798
  • [50] Medicare's use of cost-effectiveness analysis for prevention (but not for treatment)
    Chambers, James D.
    Cangelosi, Michael J.
    Neumann, Peter J.
    HEALTH POLICY, 2015, 119 (02) : 156 - 163